SOURCE: GeneThera, Inc.

June 06, 2007 11:00 ET

GeneThera's New Governance and Annual Stockholder's Meeting

WHEAT RIDGE, CO--(Marketwire - June 6, 2007) - As part of a continuing effort to improve its system of corporate governance, the GeneThera, Inc. (OTCBB: GTHA) Board of Directors recently revised the company's Corporate Governance Guidelines and created three new committees of the board of directors. The committees include: Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.

In an era of growing focus on corporate governance and transparency, GeneThera believes it's especially critical that shareholders, employees and other stakeholders understand how seriously the company takes corporate governance.

As part of the new system of corporate governance, GeneThera's board will nominate 4 independent board members for election to GeneThera's board of directors at the July 26th, 2007 meeting of the shareholders. These members shall serve as independent members of the board of directors and will serve on the newly created independent committees of the board.

Under the revised policies, the GeneThera Board of Directors formally established that the Committees shall consist of only the independent boards of directors that are up for nomination at the July Meeting of the Shareholders. The Compensation Committee shall conduct the annual review of the Chief Executive Officer and other executive officers of GeneThera. Additionally, a lead independent director will be appointed who will provide input on meeting agendas on behalf of non-management directors, call and chair meetings of the non-management directors.

"It has always been our desire to make sure our management practices and business efforts align with the interests of our stakeholders," said Dr. Tony Milici. "We will continue to evaluate our governance policies and revise them to bolster what we believe is an already strong corporate governance platform."

Additionally, GeneThera also created a new shareholder communication platform. Shareholders are encouraged to communicate with the Company with any questions regarding the Company's plan and/or operations.

E-mail communications can be sent to and/or; shareholders also may call (949) 429-4007 or (303) 463-6371, extension 204.

Shareholders are also invited to partake in monthly phone conferences that will commence in August and quarterly shareholder conferences that will be held beginning August 2007 and held every January, August and October, thereafter.


GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression system, GES a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priority being Mad Cow Disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johne's Disease, diseases affecting cattle worldwide.

Application of the Safe Harbor of the Private Securities Litigation Reform Act of 1995:

This press release contains, and GeneThera may from time to time make, written or oral "forward-looking statements" within the meaning of the U.S. federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of uncertainties and other factors, many of which are outside GeneThera's control that could cause actual results to differ materially from such statements. In particular, statements using words such as "may," "should," "estimate," "expect," "anticipate," "intend," "believe," "predict," "potential," or words of similar import generally involve forward-looking statements.

"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements.

Contact Information